Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Dapagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms BEYOND
- Sponsors AstraZeneca
- 18 Jun 2023 Results of a post-hoc analysis assessing clinical factors affecting response to dapagliflozin treatment presented at the 105th Annual Meeting of the Endocrine Society
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.
- 28 Apr 2017 Planned End Date changed from 1 Apr 2018 to 23 Jan 2018.